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Hepatitis E virus (HEV) is an under-recognised cause 
of acute hepatitis in high-income countries. The pur-
pose of this study was to provide an overview of test-
ing, diagnosis, surveillance activities, and data on 
confirmed cases in the European Union/European 
Economic Area (EU/EEA). A semi-structured survey 
was developed and sent to 31 EU/EEA countries in 
February 2016, 30 responded. Twenty of these coun-
tries reported that they have specific surveillance 
systems for HEV infection. Applied specific case defi-
nition for HEV infection varied widely across coun-
tries. The number of reported cases has increased 
from 514 cases per year in 2005 to 5,617 in 2015, with 
most infections being locally acquired. This increase 
could not be explained by additional countries imple-
menting surveillance for HEV infections over time. 
Hospitalisations increased from less than 100 in 2005 
to more than 1,100 in 2015 and 28 fatal cases were 
reported over the study period. EU/EEA countries are at 
different stages in their surveillance, testing schemes 
and policy response to the emergence of HEV infection 
in humans. The available data demonstrated a Europe-
wide increase in cases. Standardised case definitions 
and testing policies would allow a better understand-
ing of the epidemiology of HEV as an emerging cause 
of liver-related morbidity.
Introduction
Hepatitis E virus (HEV) infection is one of the lead-
ing causes of acute viral hepatitis worldwide with 
four different genotypes (1–4) responsible for most 
human infections. HEV genotype 3 predominates in 
high-income countries, including those in Europe. 
Transmission of this genotype is usually zoonotic and 
has been linked to the consumption of pork products, 
and in some instances, shellfish [1-3]. Infection, which 
is most often asymptomatic, may cause an acute self-
limiting hepatitis, with symptomatic infection more 
commonly reported among men older than 50 years of 
age [4,5]. Reports of chronic infection among immuno-
compromised people or those with pre-existing liver 
disease have been described [4].
There is evidence that HEV is an under-recognised 
pathogen in high-income countries, and that the inci-
dence of confirmed cases has been steadily increas-
ing over the last decade [6-10]. Although population 
studies have shown stable or decreasing seropreva-
lence rates [11,12], some countries have reported a 
consistently high seroprevalence and proportion of 
HEV-RNA-positive blood donors [13-16]. A systematic 
review conducted by the World Health Organization 
(WHO) reported HEV seroprevalence (as denoted by 
presence of IgG antibody) to range from 0.03% to 52% 
among the general population and blood donors in the 
WHO European Region, with the highest prevalence 
reported from studies in blood donors from France and 
the Netherlands [17]. Evidence of current HEV infection 
in up to 77% of patients presenting with symptomatic 
acute hepatitis suggests that the virus could be a con-
siderable cause of liver morbidity in European coun-
tries [17]. However, the use of different serological test 
systems significantly influences the estimates of sero-
prevalence [18].
Europe-wide surveillance is not in place for hepatitis 
E, and the European Centre for Disease Prevention and 
Control (ECDC) has launched a number of activities 
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that aim to better understand the current epidemiol-
ogy, as well as the national monitoring systems for HEV 
infection within European Union/European Economic 
Area (EU/EEA) countries. A recent study involving HEV 
experts from 17 countries documented an increase in 
reported cases in nearly all EU/EEA countries that pro-
vided data, with France, Germany, England and Wales, 
and the Netherlands reporting more hepatitis E than 
hepatitis A notifications. The study also highlighted a 
lack of consistency in the reporting of cases, and wide 
variation in surveillance activity and case definitions 
[7]. The current study builds on this work to conduct 
a wider assessment of testing, diagnosis, surveillance 
activities and confirmed cases of HEV infection in the 
EU/EEA in order to inform the Europe-wide response to 
this emerging infection.
Methods
A semi-structured survey of EU/EEA countries was con-
ducted during 2015/16. The survey was divided into 
four sections (surveillance, testing and diagnosis, data 
on diagnosed cases, and transfusion-associated HEV 
infections) to allow separate country-level respond-
ents for each topic area with a total of 24 open and 
closed questions [19]. A pilot survey was conducted at 
a meeting of the ECDC HEV expert group in December 
2015, and a revised survey was subsequently cir-
culated by email to nominated representatives of 
ECDC’s networks, the National Focal Points for Food- 
and Waterborne Diseases and Zoonoses as well as 
for Microbiology and Surveillance, in February 2016. 
Respondents were given three weeks to complete the 
survey (which could be completed electronically), and 
email and phone reminders were used to follow up with 
those who had not responded.
Returned survey data were manually extracted into 
Excel and double-checked. Any unclear responses 
were checked by email communication with the respec-
tive experts. Analyses were conducted in Excel and 
STATA version 13. The United Kingdom (UK) provided 
three separate responses (from England and Wales, 
Scotland, and Northern Ireland) which were consid-
ered as a single country response for all quantitative 
analyses and listed separately for qualitative analyses. 
A descriptive analysis was performed. The proportion 
of hospitalised cases was calculated using data exclu-
sively from countries reporting hospital data, with the 
number of total cases as denominator. The Eurostat 
Figure 1
Type of applied case definition for confirmed cases of hepatitis E virus infection in 20 European Union/European Economic 
Area (EU/EEA) countries, 2015
Non-visible countries
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Hepatitis E virus RNA persisting for at least 3 months
PCR: polymerase chain reaction; RNA: ribonucleic acid.
Administrative boundaries from EuroGraphics. Map produced on 8 June 2017.
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Figure 2
Reported number of cases of hepatitis E virus infection by year of notification and year of surveillance commencement, 22 
European Union/European Economic Area (EU/EEA) countries, 2005–2015a
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a Data available for the following countries (year of commencement of HEV surveillance/year since cases reported during study period 2005–
2015): Austria (1980/2012), Belgium (2010/2010), Bulgaria (no surveillance/2015), Croatia (2009/2009), Cyprus (no surveillance/2009), 
Czech Republic (1996/2005), Estonia (1997/2005), Finland (1995/2005), France (2002/2005), Germany (2001/2005), Hungary (1993/2005), 
Italy (2007/2007), Latvia (commencement unknown/2007), the Netherlands (2012/2012), Norway (no surveillance/2005), Poland (no 
surveillance/2014), Portugal (commencement unknown/2014), Slovakia (2007/2005), Slovenia (1995/2005), Spain (commencement 
unknown/2006), Sweden (1993/2005), and UK (England and Wales (2003/2005), Scotland (2000/2005) and Northern Ireland 
(unknown/2005).
Figure 3
Number and proportion of hospitalisations among reported cases of hepatitis E virus infection, 14 European Union/
European Economic Area (EU/EEA) countries, 2005–2015a
Countries reporting hospitalisations from 2007 onwards
Countries reporting hospitalisations since at least 2005
Proportion of confirmed cases that are hospitalised
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
0
200
400
600
800
1,000
1,200
2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Pr
op
or
tio
n 
of
 h
os
pi
ta
lis
ed
 a
m
on
g 
re
po
rte
d 
ca
se
sb
Nu
m
be
r o
f h
os
pi
ta
lis
at
io
ns
Year of diagnosis
 a Data available for (year of first report): Austria (2012), Belgium (2010), Croatia (2012), Czech Republic (2005), Estonia (2012), Germany 
(2005), Hungary (2005), Italy (2007), Latvia (2007), Poland (2014), Portugal (2015), Slovakia (2005), Slovenia (2005) and the UK (Northern 
Ireland) (2013).
b Proportion of hospitalisations only included denominator data from countries reporting both number of reported cases and number of 
hospitalised cases.
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population database from 2015 was used as source of 
population denominator data [20].
Results
All EU/EEA countries with the exception of Liechtenstein 
responded to the survey, giving a response rate of 30 
out of 31. The data provided from countries that con-
duct surveillance was comprehensive, detailed and of 
high quality.
Hepatitis E surveillance systems
Of 30 responding countries, 20 had specific surveil-
lance systems for HEV infection. The remaining 10 
countries had more generic viral hepatitis syndromic 
surveillance with no plans to develop any specific 
surveillance for HEV infection. Of the 20 EU/EEA coun-
tries with specific systems for HEV infection, 15 had 
national surveillance systems, three had laboratory 
surveillance through national reference laboratories 
with unknown coverage, one had blood service surveil-
lance with unknown coverage, and one had a sentinel 
surveillance system covering approximately half of the 
population.
Thirteen of 20 surveillance systems specific for HEV 
infection had a case definition for confirmed cases. 
There was wide variation in the type of case defini-
tion used: seven used laboratory and clinical defini-
tions, and six used a laboratory definition only (Figure 
1). Most surveillance systems collected demographic 
information as well as the date of notification and 
onset of disease, whereas morbidity and mortality data 
were collected less frequently (Table 1). Two countries’ 
surveillance systems (Ireland and the UK (England and 
Wales)) differentiated between acute and chronic HEV 
infection: acute infection was defined as both HEV-
IgM-positive and IgG-positive, or HEV-RNA-positive, 
and chronic infection was defined as HEV RNA persist-
ing for at least 3 months.
Hepatitis E testing and diagnosis
Twenty-six countries conducted HEV testing in their 
own countries, with two countries sending samples 
abroad for testing and two reporting their testing avail-
ability as unknown. In 12 countries, there were less 
than five laboratories able to conduct diagnostic tests 
for HEV. Laboratories in 20 countries used more than 
one type of test (Table 2). For HEV antibody testing in 
acute cases, IgM ELISA was used in 21 countries and 
IgM Western Blot in 11. Of the 22 countries using any 
IgM antibody test, 20 also used IgG ELISA and nine 
IgG Western Blot for the detection of IgG antibodies. 
Nineteen countries reported that they were able to 
conduct HEV RNA testing; all used serum/plasma and 
12 also used stool specimens. Seventeen countries 
reported that HEV sequencing was conducted for epi-
demiological investigations (15 countries), for research 
purposes (14 countries) or as routine practice (10 coun-
tries). Ten countries provided information on why a lab-
oratory might conduct a test for HEV. Two countries had 
a laboratory policy on testing for HEV: (i) UK (Scotland), 
where some laboratories automatically test for HEV if 
alanine transaminase (ALT) was ≥ 100 U/L, and (ii) 
Ireland, where an HEV test is automatically conducted 
if a test for hepatitis A virus (HAV) is requested. The 
remaining countries reported that HEV testing was con-
ducted only at the request of a clinician.
Confirmed cases of hepatitis E virus infection
Twenty-two countries covering 469 million people (i.e. 
91% of the EU/EEA population of 514 million people) 
provided data on confirmed cases of hepatitis E (Figure 
2). The total number of reported cases increased 
from 514 cases in 2005 to 5,617 cases in 2015, with 
21,018 cases overall during the 11-year period stud-
ied (Figure 2). A total of 93% (19,531/21,018) of cases 
were accounted for by countries that have had hepati-
tis E-specific surveillance since at least 2005, and 80% 
(16,810/21,018) of cases were reported from just three 
countries (Germany, France, and the UK), which com-
prise 41% of the EU/EEA population. In 16 countries 
providing data on the age of reported cases, the overall 
proportion of those aged more than 50 years increased 
from 30–47% during 2005–2008 to 60–61% during 
2013–2015. In 17 countries providing data on the sex of 
reported cases, the proportion of male cases remained 
stable over 2005–2015, ranging from 61% in 2005 and 
2015 to 69% in 2006.
Severity associated with hepatitis E virus 
infection
Data from 14 countries reporting on the total number 
of hospitalisations related to HEV infection showed 
an increase from 85 hospitalised cases in 2005 to 
Figure 4
Reported cases of hepatitis E virus infection by year 
of notification and travel history, 15 European Union/
European Economic Area (EU/EEA) countries, 2005–2015a
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1,115 in 2015 (Figure 3). Most of this increase could be 
accounted for by four of the five countries that have 
conducted reporting on hospitalisation status since 
at least 2005. Over the same time period, the propor-
tion of cases being hospitalised has decreased from 
80% (85/106 cases) to 55% (1,115/2,023 cases). Twelve 
countries provided data on deaths associated with HEV 
infection, with five countries recording these data since 
2005. In total, 28 fatal cases were reported by five 
countries (Austria, Czech Republic, Germany, Hungary 
and Italy), increasing from 0–2 cases per year during 
2005–2011 to 4–8 cases per year during 2012–2015.
Travel history of diagnosed cases
Fifteen countries provided data on travel history. Of 
hepatitis E cases reported in these countries dur-
ing the period 2005–2015, 87% (13,511/15,525) were 
autochthonous (defined as locally acquired within the 
reporting country). The proportion of known autoch-
thonous cases increased from 45–73% per year dur-
ing 2006–2011 to 89–97% per year during 2012–2015. 
This suggests that the considerable increase in con-
firmed cases observed after 2011 (Figures 2 and 4) can 
largely be accounted for by locally acquired infection. A 
very small number of cases per year (9–36 cases) were 
known to be associated with travel outside of the EU/
EEA.
Discussion
This study assessed testing policy and practice, labo-
ratory diagnosis, and surveillance systems and activi-
ties for HEV infection in 31 EU/EEA countries. Thirty 
of the countries responded to the survey, provid-
ing the most comprehensive picture to date of HEV 
as an emerging infection among humans in Europe. 
The 10-fold increase in the number of cases reported 
between 2005 and 2015, more than 21,000 confirmed 
cases overall and a total of 28 deaths, underline the 
relevance and emerging nature of this zoonotic infec-
tion in Europe.
The survey findings demonstrate a varied response to 
hepatitis E across EU/EEA countries; while two thirds 
of countries have established surveillance systems, 
a third of countries have no specific surveillance 
and no plans to develop any. For those with existing 
surveillance, nearly one third do not apply a case defi-
nition for HEV infection nationally. Only 19 countries 
reported that they were able to conduct HEV RNA test-
ing in-country, although there may be testing within 
hospitals or private settings that the national public 
health institutes or survey respondents are unaware of. 
In most countries, it was not possible to ascertain the 
criteria for referral or for HEV test requests. While there 
may be an increasing awareness of locally acquired 
HEV infections, there is still concern that within parts 
of the clinical community, HEV is not considered as 
a possible cause of hepatitis unless there is a recent 
history of travel. It is therefore likely that the infection 
remains under-diagnosed. There also appears to be a 
gap in knowledge around the testing protocols used 
in outpatient and hospital settings within countries, 
which should be investigated further to understand 
when, who, and why patients are tested for HEV.
Twenty-two countries (comprising more than 90% of 
the total EU/EEA population) were able to provide data 
on confirmed cases for at least some of the period 
2005–2015. These data demonstrate that the number 
of reported cases has been increasing year-on-year, 
with a more than threefold increase between 2011 and 
2015. The majority of cases were reported by three 
countries (the UK, France and Germany) that have had 
surveillance systems in place since at least 2005. A 
small number of countries reported changes to surveil-
lance systems during the study period; for example, 
Belgium created a national reference centre for HEV in 
2011 and Portugal commenced web-based notification 
in 2014. However, there were no changes that could 
have contributed substantially to the increase in the 
number of confirmed cases. A greater awareness of 
and increased testing for HEV, particularly of patients 
presenting with acute hepatitis by general practition-
ers in outpatient settings, is likely to be one of the 
contributing factors e.g. through the inclusion of HEV 
in some standard diagnostic protocols. The rise in the 
number of symptomatic cases might also be related to 
the switch in virus subtypes that has been observed in 
some EU/EEA countries [7,21].
The concurrent increase in number of hospitalisations 
(a measure of increased HEV infection severity) and 
Table 1
Variables collected by specific surveillance systems for hepatitis E virus infection in 20 European Union/European 
Economic Area (EU/EEA) countries, 2015
Countries collecting data on hepatitis E cases 
via their surveillance systems Variables
Majority (> 14 countries) Unique patient identifier, date of notification, source of notification, date of birth, sex, date of onset of disease
Some (6–14 countries) Date of diagnosis, cluster link, occupation, pregnancy, clinical symptoms, travel, food history, contact with animals, hospitalisation, death
Few (< 6 countries) Ethnicity, migration status, alcohol consumption, medication, immunosuppressive medication or condition, other medical conditions, past transfusion/transplantation
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gradual decrease in proportion of total cases hospital-
ised between 2005 and 2015 may suggest better out-
patient diagnosis and an increase in the sensitivity of 
the diagnostic system, i.e. a change in testing practice 
from hospitals to community settings. For cases where 
clinical information was recorded, every second case 
was admitted to hospital and there were two to eight 
deaths associated with HEV infection annually during 
2011–2015. These figures appear high for a disease 
that has previously been considered to be a mild self-
limiting infection [22]. However, a testing bias and over-
estimation of the hospitalisation rate can be assumed 
because of a higher likelihood that cases of severe 
liver disease or other comorbidities are tested for HEV. 
Notably, only four countries were able to provide data 
on morbidity status since 2005 and only five were able 
to provide data on case fatality since 2005, although 
nearly half of the EU/EEA countries indicated that they 
are able to collect this information as of 2015. More 
data are needed to address the lack of knowledge in 
this area.
As our results show, the number and proportion of 
autochthonous HEV infections has been increasing 
since 2005. Only a very small number of cases were 
known to be related to travel outside of the EU/EEA. 
Although genotype data were not requested from coun-
tries, it is known that autochthonous cases tend to be 
due to HEV genotype 3, the same genotype present in 
European pigs and consumed pork products; travel-
related cases would be expected to be infected with 
genotype 1 or 4 [2-5]. Lately, there appears to have 
been a change in circulating subtypes in Europe. For 
example, the number of subtype 3c recently exceeded 
the numbers of subtypes 3e, f and g in humans in 
England and Wales [21]. Such changes may be con-
tributing to the emergence of HEV as an important 
infection in humans. Changes in the pattern of food 
preparation and consumption may also be implicated. 
A case–control study in England and Wales identified 
pork sausages and ham purchased in supermarkets as 
possible sources of infection, raising concerns about 
whether current practice in preparing these products 
is sufficient to prevent HEV infection [23]. More stud-
ies among humans, animal populations and on food 
are essential to informing on possible sources of HEV 
infection.
The main limitations of this study are the variation in 
the denominator data for reported cases of hepatitis E 
(most countries were only able to provide a subset of 
demographic information or a limited number of years 
of data) and the merging of data on reported cases of 
hepatitis E despite the different case definitions and 
testing approaches used by EU/EEA countries. These 
limitations have in part been addressed by showing 
data by year of surveillance introduction and by limit-
ing the denominator to cases where the relevant infor-
mation was known. The varying number of countries 
providing data inconsistently over the study period 
prompted us not to perform any trend analysis to avoid 
further introduction of bias. In the future these limita-
tions could be addressed by standardisation of surveil-
lance systems for HEV infection, harmonisation of the 
case definition as well as testing algorithms across EU/
EEA countries. This would enable better assessment of 
the burden of disease due to HEV in Europe and facili-
tate a better understanding of the actual number of per-
formed tests or population coverage as a denominator, 
thus avoiding diagnostic and surveillance artefacts.
In summary, EU/EEA countries are at different stages 
in their surveillance and testing capacity for HEV, and 
there is no standardised European case definition. 
For the time period 2005–2015, at least 22 countries 
were able to report on cases infected with HEV, either 
through formal surveillance or existing systems of 
laboratory notifications. WHO’s global health sector 
strategy on viral hepatitis asks countries to establish 
surveillance for viral hepatitis, particularly in blood 
donors [24]. Our study describes the availability of 
general hepatitis E surveillance in most EU/EEA coun-
tries. These data demonstrate a Europe-wide increase 
in reported cases, as well as a high number of reported 
HEV-related hospitalisations and a total of 28 deaths, 
between 2005 and 2015. They also provide a better 
understanding of the epidemiology and burden of HEV 
as an emerging cause of liver-related morbidity in EU/
EEA countries.
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